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Intentional drug overdose (IDO) has been linked with marked increases in mortality due to suicide, 
accidents and other causes, yet little is known about how case fatality risk varies according to the type 
of drug/s taken. This study aimed to examine the incidence fatal and non-fatal IDO, to identify the 
predictors of fatal IDO and to establish which drug types are linked with greater risk of a fatal outcome. 
Methods 
Data from the National Self-Harm Registry, Ireland and the National Drug-Related Deaths Index, 2007-
2014, were used to calculate incidence, examine overdose characteristics and estimate case fatality 
risk ratios. 
Results 
We examined 63,831 non-fatal and 364 fatal IDOs (148.8 and 1.01 per 100,000 respectively). 
Compared to non-fatal IDOs, fatal cases were often male (55.2% vs. 42.0%), older in age (median 44 
vs. 35 years), and more frequently involved multiple drugs (78.3% vs. 48.5%). Tricyclic antidepressants 
were associated with a 15-fold increased risk of death and opioids a 12-fold increased risk, relative to 
the reference category (non-opioid analgesics). While the risk of fatal outcome was higher for males 
than females, the elevation in risk was greater in females when tricyclic antidepressants or opioids were 
taken in IDO.  
Conclusion 
Male gender, increasing age and multiple drug use were associated with fatal IDO outcome. Tricyclic 
antidepressants and opioids were associated with a significantly increased risk of death following 
overdose. Clinicians need to consider the case fatality risk of drugs when determining treatment for 
patients at risk of or those who have previously harmed themselves.  
 




Introduction: Intentional drug overdose (IDO) is the most common method of hospital-presenting non-
fatal self-harm (Perry, et al., 2012; Vancayseele, Portzky, & van Heeringen, 2016), and is associated 
with an increased risk of repeat self-harm (Finkelstein, et al., 2016), which when combined with another 
method, such as self-cutting, can increase by 50% (Kwok, Yip, Gunnell, Kuo, & Chen, 2014). The risk 
of mortality due to suicide is also increased among persons who have engaged in IDO, as are deaths 
due to other causes, including accidental deaths, those of undetermined intent and those caused by 
underlying disease (Finkelstein, Macdonald, Hollands, Hutson, et al., 2015a; Finkelstein, Macdonald, 
Hollands, Sivilotti, et al., 2015b).  
Intentional drug overdose resulted in 7,792 presentations to Irish hospitals in 2018 (Griffin, et al., 2019), 
and accounts for approximately 68-84% of all hospital treated self-harm presentations, most of which 
involve females and persons under 40 years of age (Daly, et al., 2018; Vancayseele, Rotsaert, Portzky, 
& van Heeringen, 2019). Fatal IDO results in approximately 40 deaths in Ireland annually (CSO, 2014), 
and accounted for approximately 889 deaths in England and Wales in 2018 (ONS, 2019), of which the 
majority were male. Considering drugs taken, non-fatal IDOs most frequently involve non-opioid 
analgesics, antidepressants and hypnotics and sedative (including benzodiazepines) drugs (Daly, et 
al., 2018; Vancayseele, et al., 2019), and fatal IDOs most commonly involve opioid and benzodiazepine 
drugs (HRB, 2015; Pringle, et al., 2017). 
The type of drug taken in IDO varies according to individual characteristics, geography and across time 
periods, and is one of several key factors that influence the likelihood of repeat IDO and subsequent 
fatality following overdose (Finkelstein, et al., 2016; Geulayov, et al., 2018). Research in the UK which 
measured case fatality of single-drug overdoses with antidepressants and benzodiazepines attributed 
high fatality to the antidepressants dosulepin doxepin, citalopram (Hawton, et al., 2010), and to the 
benzodiazepine and hypnotic drugs temazepam and zopiclone/zolpidem (Geulayov, et al., 2018). A 
subsequent study in the USA examined the fatality of drugs used in all poisoning deaths (intentional 
and accidental) over a 16-year period, and identified opioids as the most toxic drug examined, followed 
by tricyclic antidepressants (Brett, Wylie, Raubenheimer, Isbister, & Buckley, 2019). 
Establishing the potential fatality of and IDO is undermined by the frequent involvement of a combination 
multiple drugs in overdose. Multiple drugs are present in between 26 and 41% of non-fatal IDOs (Daly, 




involvement of multiple drugs in non-fatal and particularly fatal IDO, the case fatality of drugs taken in 
multiple drug overdoses remains under examined and has not yet been established in relation to suicide 
deaths. Insights into the case fatality of drugs used in both single and multiple drug IDOs which would 
aid clinicians in determining assessment and treatment pathways for patients who are at risk of or have 
previously engaged in IDO.  
This study aimed to identify the incidence and characteristics of fatal and non-fatal IDO, including single 
and multiple drug IDOs, and, to establish which drug types are most strongly linked with a fatal outcome, 
according to case fatality risk estimates. 
Method: This was an observational study using data pertaining to the period 1st Jan 2007 to 31st Dec 
2014, which examined two unlinked datasets that captured fatal IDO cases in the National Drug-Related 
Deaths Index, Ireland (NDRDI) and non-fatal IDO presentations in the National Self-Harm Registry, 
Ireland (NSHRI).  
Non-fatal hospital-treated IDO presentations 
The NSHRI, which is administered by the National Suicide Research Foundation (NSRF), monitors 
hospital-treated self-harm across all 36 acute hospitals in the Republic of Ireland, using the following 
definition of self-harm: ‘an act with non-fatal outcome in which an individual deliberately initiates a non-
habitual behaviour, that without intervention from others will cause self-harm, or deliberately ingests a 
substance in excess of the prescribed or generally recognised therapeutic dosage, and which is aimed 
at realising changes that the person desires via the actual or expected physical consequences’ (Platt, 
et al., 1992). Data on self-harm presentations are collected by Data Registration Officers (DROs), 
including items detailing: sex, age, area of residence, date and hour of hospital attendance, whether 
the individual arrived by ambulance, method(s) of self-harm, drugs taken, medical card status, mental 
health assessment and recommended next care received. A maximum of 5 methods are recorded for 
presentations involving multiple methods. We examined non-fatal IDO presentation-based data, 
identified as having ICD-10 codes X60-X64. Presentations of IDO involving other agents, such as 
chemicals (ICD-10 X66-X69), and alcohol-only self-poisoning cases (ICD-10 X65) were excluded. 
Drugs taken in IDO are captured in the NSHRI via self-reported information from the patient, ambulance 
service records, hospital medical records, and toxicology reports if available. Information pertaining to 




Fatal IDO cases 
Deaths by IDO were identified via the NDRDI, which records all deaths by drug and/or alcohol 
poisoning, and deaths among drug users and those who are alcohol dependent, in persons aged over 
15 years in the Republic of Ireland. Fatal cases where the coroner returned a suicide or ‘open’ verdict 
(i.e. unnatural death of undetermined cause), following a completed inquest procedure, were included 
in this study. Open verdicts are customarily included in suicide statistics as these cases have been 
shown to have similar characteristics to suicides, often representing probable suicides where the 
evidence was insufficient to prove that the individual intended to take their own life (Linsley, Schapira, 
& Kelly, 2001). Fatal IDO cases are those that occurred directly due to the toxic effects of the drug(s) 
taken. Non-poisoning deaths, deaths by alcohol only (ICD-10 X65), chemical poisonings (ICD-10 X66-
X69), and deaths with no coronial verdict, or with a verdict of misadventure, were excluded. Relevant 
information collected on each fatal IDO case included: sex, age date of death and post-mortem 
toxicology results - including whether a drug was involved in death or caused the death, as reported on 
the individual’s death certificate.  
Drugs certified as a cause of death or involved in death 
Post-mortem blood and urine samples are screened in local hospital laboratories using immunoassay 
analysis to identify the involvement of particular drugs in death. Further identification and quantification, 
is provided by the State Laboratory for Human Toxicology which, together with information from the 
State Pathologist, assists the responsible Coroner in interoperating whether or not to certify a drug as 
involved in death or as causing the death. One or more drugs can be registered in the individuals’ 
certificate as being involved in death or as having caused death. 
Classification of drugs 
We reported on the drug types frequently used in IDO, as determined by Daly et al., 2018 (Daly, et al., 
2018). The Anatomical Therapeutic Chemical (ATC) classification system was applied to the drugs 
examined in this study, the detail of which can be found in the Guidelines for ATC Classification and 
DDD Assignment (WHO, 2019). The ATC codes for the drug types reported are: psycholeptics ‘N05’; 
analgesics ‘N02’; opioids ‘N02A’; morphine containing drugs ‘N02AA01’, ‘N02AG01’, ‘N02AA51’; 
oxycodone containing drugs ‘N02AA05’, ‘N02AJ17’, ‘N02AJ18’, ‘N02AJ19’; tramadol containing drugs 




sedatives ‘N05C’; antipsychotics; ‘N05A’; psychoanaleptics ‘N06’; selective serotonin reuptake 
inhibitors (SSRIs) ‘N06AB’; fluoxetine ‘N06AB03’; citalopram ‘N06AB04’; sertraline ‘N06AB06’; tricyclic 
antidepressants ‘N06AA’; amitriptyline ‘N06AA09’; dosulepin ‘N06AA16’; trimipramne ‘N06AA06’; 
antiepileptics ‘N03’;  benzodiazepines ‘N03AE’, ‘N05BA’, ‘N05CD’ and ‘N05CF’. Illicit drugs were 
identified using the Irish Misuse of Drugs Acts of 1977 and 1984 (Misuse of Drugs Act 1977, Misuse of 
Drugs Act 1984); and are listed in the Supplementary Material, item ‘Illicit Drugs List’. Multiple drug use 
refers to the involvement of two or more distinct drug types per IDO presentation, whereas single drug 
use refers to the taking of just one drug type, both of which excluded alcohol misuse.  
Statistical analyses and reporting 
Annual gender- and age-specific incidence rates per 100,000 persons were calculated using the 
numbers of non-fatal and fatal IDO cases recorded and the national Census population data for 2011 
and the Central Statistics Office annual population estimates for other years. We calculated 95% 
confidence intervals using the Poisson distribution. Case fatality risk represent the proportion of IDOs 
which are fatal according to the demographic or drug group under examination. Case fatality risk ratios 
represent the ratio of the case fatality risk of the particular demographic or drug group being examined 
relative to the reference category. Non-opioid analgesics were chosen as the reference category for 
drugs examined in Table 2 as they are among the most frequently used drugs taken in IDO (Daly, et 
al., 2018). The reference categories for Table 3 are amitriptyline, and tramadol and fluoxetine, which 
represent the most common tricyclic antidepressants, SSRIs and opioids used in IDO, respectively. 
Case fatality risk ratios presented within the main text of the paper refer to drugs that were certified by 
Coroners’ certificates as being the cause of death, and were calculated from an age- and gender-
adjusted Poisson regression model. An additional sensitivity analysis was conducted to estimate the 
case fatality risk ratios of drugs involved in death, and are provided in the Supplementary Material 
(Table 2, 5 and 6).  
A process of weighting was performed to address the challenge of calculating case fatality risk and 
case fatality risk ratios when multiple drugs had been certified as causing death. Case fatality risk ratios 
presented within this paper are weighted, whereby the drug of interest is counted as half within the 
reference drug group and half within the drug group of interest, in which the two aforementioned drug 




calculate alternative case fatality risk ratio estimates whereby the drug of interest was either counted in 
both its drug group or that of the reference group (‘Double count’) or in neither (‘Excluded in count’). 
These additional sensitivity analyses, which are provided in the Supplementary Material (Tables 2, 4 
and 5), offer alternative analytical approaches for estimating the relative fatality of IDOs according to 
the type of drug (or drugs) taken. 
Cell counts of less than five for fatal cases were masked in all tabulations. Analyses were conducted 
using SPSS v.22. Statistical significance was reported at three thresholds: p≤0.05, p≤0.01 and p≤0.001. 
The conventional levels of p≤0.05, p≤0.01 are reported to allow for comparability with other research. 
The stringent threshold of p≤0.001 was used to highlight the most significant associations, which is 
important when examining a dataset of this size. Case fatality risk ratio weighting was performed using 
Excel formulae, and StataIC 12 was subsequently employed to calculate the case fatality risk ratios and 
accompanying confidence intervals and significance values.  
The reporting of this study conforms to the Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) statement: guidelines for reporting observational studies. 
Ethical approval 
The NSHRI has ethical approval from the National Research Ethics Committee of the Faculty of Public 
Health Medicine, Ireland. The NSHRI operates under a policy approving a waiver of consent. These 
patients have the right to opt out of having their data collected and used for research via a system that 
is described in patient leaflets placed in the emergency department, and reserve all the rights of data 
subjects as outlined in the current General Data Protection Regulation (GDPR) 2018 regulations. The 
NDRDI has ethical approval from the Health Research Board (HRB) ethics committee. 
Data access 
The NSRF is registered with the Data Protection Agency and complies with the Irish Data Protection 
Act of 1988 and the Irish Data Protection (Amendment) Act of 2003. All data were anonymised and 






This study was co-funded by the NSRF and by the University of Manchester, under no specific grant 
funding. The NSHRI is funded by the Health Service Executive’s National Office for Suicide Prevention. 
Results 
Characteristics of non-fatal and fatal IDOs 
Between 1st January 2007 and 31st December 2014 there were 64,195 IDOs, 63,831 of which were 
non-fatal, and 364 of which were fatal. Of the fatal IDO cases, 46.2% (168) had received a verdict of 
suicide and 196 an open verdict. The majority of fatal cases were male (55.2%) and the median age of 
these persons was 44 years (IQR: 33-53). Non-fatal IDO presentations were most often made by 
females (58.0%) and the median age reported was 35 years (IQR: 23-44). Multiple drug use was a 
factor in 78.3% of fatal IDOs and 48.5% of non-fatal episodes.  
[Figures 1a and 1b here] 
Incidence of non-fatal and fatal IDOs 
Figures 1a and 1b illustrate the non-fatal and fatal IDO incidence rates stratified by age and gender. 
Overall, the rate of non-fatal IDO was 148.8 per 100,000 (95% CI 147.5-150.1) and the rate of fatal IDO 
was 1.01 (0.90-1.11). The incidence of non-fatal IDO was higher for females and peaked for persons 
aged 15-24 years whereas the rate of fatal IDO was higher for males and highest among persons aged 
45-54 years, as illustrated in Table 1 and reported in Supplementary Table 1.  
[Table 1 here] 
Case fatality by gender, age and number of drugs 
Examining case fatality, the risk of death following an IDO was 1.7 times greater for males, compared 
to females (CFRR=1.70; 1.38-2.09, p≤0.001), as reported in Table 1. The risk of death increased with 
age and was over five times greater for those aged 45 years or older (CFRR=5.63; 3.91-8.11, 
p=≤0.001), compared to those aged 15-24 years. Multiple drug IDOs were over three times more likely 
to be fatal compared to single drug IDOs (CFRR=3.80; 2.96-4.88, p≤0.001). Intentional drug overdoses 
involving between two and five different drugs were three times more likely to be fatal (CFRR=3.13; 




more likely to result in death (CFRR=60.5; 42.7-85.7, p≤0.001), compared to IDOs involving one drug. 
The involvement of alcohol did not increase risk of death in this study (CFRR=1.07; 0.87-1.32, p0.538). 
[Table 2 here] 
Drugs frequently taken in IDO  
Psycholeptic drugs, the majority of which were benzodiazepines, were the drug type that most 
frequently caused death or were involved in non-fatal IDO, as reported in Table 2. Considering non-
fatal IDOs, non-opioid analgesics were also frequently taken, with an incidence rate of 50.0 per 100,000 
(49.3-50.8). Opioid and tricyclic antidepressant drugs had the lowest rates of involvement in non-fatal 
IDO at 7.85 (7.56-8.15) and 3.63 per 100,000 (3.43-3.83), respectively. Examining fatal IDOs, the 
frequent use of psycholeptic drugs was followed by antidepressant drugs at 0.39 (0.33-0.46). Owing to 
the larger number of female non-fatal IDO presentations, compared to males, the rates for all drugs 
used in non-fatal acts, excluding illicit drugs are higher for females. Greater gender disparities are 
reported for fatal IDOs, where females have higher rates of IDOs involving antipsychotic and 
antidepressant drugs, as illustrated in Table 2. The incidence patterns were similar for drugs that were 
involved in death and for drugs involved in single drug IDOs, as reported in Supplementary Tables 2 
and 3.  
Case fatality of drugs which caused death 
Table 2 reports on the case fatality of drugs that were deemed ultimately by the Coroners to have 
caused death. The risk of death following IDO was 15 times greater when a tricyclic antidepressant was 
taken (CFRR=15.1; 9.90-23.12, p≤0.001), compared to the reference drug category (non-opioid 
analgesics). Opioid drugs were associated with over a 12-fold increased risk of death (CFRR=12.9; 
8.60-19.3, p≤0.001). Both antidepressant and illicit drug IDOs were over four times more likely to result 
in death (CFRR=4.46; 3.06-6.49, p≤0.001 and CFRR=4.02; 2.36-6.86, p≤0.001). Antiepileptic and 
anxiolytic drugs were associated with the lowest fatality risk ratios among the drug types examined 
(CFRR=1.96; 1.17-3.29, p0.010 and CFRR=2.08; 1.39-3.10, p≤0.001).  
Examining fatality risk by gender, as shown in Table 3, the elevation in risk compared to the reference 
drug for females, was approximately three times the risk elevation of males when tricyclic 




which was not apparent for female vs. male SSRI overdose IDO (CFRR=3.01; 1.73-5.24, p≤0.001 vs. 
3.32; 1.80-6.13, p≤0.001). When illicit drugs were taken in IDO the risk of a fatal outcome is slightly 
elevated for males, compared to females (CFRR=4.20; 2.27-7.76, p≤0.001 vs. 3.29; 1.00-10.8, 
p≤0.001). These patterns were essentially replicated when drugs involved in death were examined, 
although the magnitude of the difference was smaller; and also when we implemented alternative 
approaches for estimating the case fatality risk ratio, as reported in Supplementary Tables 5 and 6. 
Considering single drug IDOs, opioids were the drug type identified as most fatal in IDO (CFRR=11.69; 
3.73-36.7, p≤0.001), as highlighted in the Supplementary Table 3. The alternative means by which 
CFRR were calculated (double count and excluded in count) are presented, with very minor variations 
in estimates found, as reported in Supplementary Table 4).  
Case fatality of individual drugs which caused death 
Considering individual tricyclic drugs, trimipramine or dosulepin were not found to confer any additional 
risk of death, compared to amitriptyline (CFRR=0.73; 0.18-3.02, p0.662 and CFRR=0.93; 0.49-1.76, 
P0.827 respectively), as reported in Table 3. Consuming the SSRI citalopram in IDO was associated 
with a 5-fold increased risk of death, compared to fluoxetine (CFRR=5.26; 2.55-10.85, p≤0.001).  Both 
morphine and oxycodone, which are opioid drugs, were associated with significant increased risk of 
fatality following IDO, compared to the reference drug tramadol (CFRR=4.16; 2.11-8.19, p≤0.001 and 
CFRR=3.94; 2.30-6.77, p≤0.001). This elevation in risk was higher for females than males, particularly 
so when morphine was consumed in IDO (CFRR=6.67; 2.54-17.5, p≤0.001 vs. CFRR=2.85; 1.12-7.28, 
p0.028), as illustrated in Table 3. 
Discussion 
Main findings and interpretation 
To our knowledge this is the first study which estimated case fatality risk associated with IDOs involving 
multiple drug types, which we examined using robust data from two national routinely collected 
datasets. We found that tricyclic antidepressants and opioid drugs are associated with a significantly 
increased risk of death following IDO, and this relative risk was greater in females than males when 
these drugs were taken. Male gender, increasing age and multiple drug use were found to be strong 




The consumption of tricyclic antidepressants in IDO was linked with an approximate 15-fold increased 
risk of subsequent death versus non-opioid analgesics. The findings of this study builds upon other 
research that has attributed a high level of toxicity to tricyclic antidepressants (Hawton, et al., 2010). 
The UK National Institute for Health and Care Excellence (NICE) clinical guideline (CG133) 2011, 
recommends “When prescribing drugs for associated mental health conditions to people who self-harm, 
take into account the toxicity of the prescribed drugs in overdose…In particular, do not use tricyclic 
antidepressants, such as dosulepin, because they are more toxic” (NHS, 2011). However, Carr et al., 
2016 identified that approximately one in ten patients who have recently harmed themselves continue 
to be prescribed these drugs (Carr, et al., 2016). Subsequent NICE pathway guidelines continue to 
emphasise the risk of IDO with tricyclic antidepressants in persons with identified suicide risk (NICE, 
2018). Considering the risks of fatal overdose which are associated with tricyclic antidepressants, action 
beyond recommendations is perhaps needs in order to protect patients at risk of overdosing with these 
drugs. Within this study no individual tricyclic antidepressant stood out as attributing excessive case 
fatality which is dissimilar to previous research which identified dosulepin and doxepin as more toxic 
than other tricyclic drugs (Hawton, et al., 2010), which could be due to the involvement of small numbers 
of individual tricyclics in fatal IDOs. However, the identification of the SSRI citalopram as five times 
more toxic than the reference SSRI drug (fluoxetine) builds upon the finding of excessive risk associated 
with this particular drug by Hawton et al., 2010. Therefore, notwithstanding the current evidence which 
recommends SSRI prescribing in the place of tricyclics, where appropriate and indicated, the risk 
associated with SSRIs, particularly citalopram cannot be undermined.  
Despite having a relatively low rate of involvement in IDO among the drug types examined, opioids 
were associated with a 12-fold increased risk of death following IDO, versus non-opioid analgesics. The 
rate of non-fatal opioid IDO identified in this study (7.70 per 100,000; 95% CI: 7.41-8.00) is similar to 
the most recent national prevalence estimates of opioid users in Ireland, as of 2014, (6.18 per 100,000; 
95% CI: 6.09-6.98). The OECD recently reported that the recent increases in opioid deaths in Ireland 
was among the most pronounced of the 25 countries examined, whereby the rate per million inhabitants 
stands at one third that of the USA (43.5 versus 131.0 per million) (OECD, 2019), highlighting a 
significant threat to public health. The fatality of an opioid overdose has been found to increase if: the 
overdose involves the co-ingestion of other drugs (predominantly benzodiazepines) (Sgarlato & 




Proescholdbell, Creppage, & Asbun, 2017), the patient was on a high dose of opioid prescription 
(Bohnert, et al., 2011; Ilgen, et al., 2016), and if the individual had previous opioid overdose 
hospitalisation (Kelty & Hulse, 2017). One commonality between these precipitating factors is the 
involvement of a healthcare professional, signalling an opportunity for intervention, however the 
evidence base for measures to reduce opioid overdose deaths is not yet comprehensive. Some 
emerging evidence illustrate effectiveness for naloxone distribution interventions (McDonald & Strang, 
2016) and treatments involving medications for opioid use disorder (Sordo, et al., 2017). A systematic 
review by Frank et al., 2017 also found some evidence, albeit of low quality, supporting opioid tapering 
in an environment whereby the patient is monitored for any adverse effects of dose-tapering (Frank, et 
al., 2017). Considering the high potential for fatality following opioid IDO and the established increase 
in opioid deaths, additional research, of greater quality, is needed to examine the potential impact, 
including dangers, associated with risk reduction measures.  
Benzodiazepines are among the most frequently used drugs taken in IDO, yet the risk of death following 
IDO involving these drugs was among the lowest of the drug groups examined. This finding, albeit with 
a weaker observed association, concurs with findings reported from other research (Geulayov, et al., 
2018). Measures identified to reduce repeat or fatal IDO with benzodiazepines include: conducting an 
assessment of suicide risk with patients prior to prescribing a benzodiazepine (Dodds, 2017), and 
lowering benzodiazepine dosage (Okumura & Nishi, 2017), however whilst dose-tapering, in 
conjunction with non-pharmacological interventions are effective benzodiazepine discontinuation 
measures, similar to the use of does-tapering intervention for opioid overdose, it is unknown whether 
reduction strategies could result in potential adverse effects for patients ( Canadian Agency for Drugs 
and Technologies in Health, 2015). Another outstanding key factor warranting further research is the 
frequency with which benzodiazepines are being prescribed with other potentially toxic medications, 
including opioids, as this can increase the risk of a fatal outcome. 
In line with the wider literature on self-harm and suicide, the incidence of non-fatal IDO reported in this 
study were higher for females (Finkelstein, et al., 2016) although risk of dying by IDO was higher for 
males (Jansen, Buster, Zuur, & Das, 2009). This paradox is often attributed to gender-related 
differences in method choice (Cibis, et al., 2012), intent (Freeman, et al., 2017) or the disproportionate 
gender distribution of depressive disorders (Alonso, et al., 2004). The increased fatality for males 




accountable for differences in case fatality between genders. This study identifies variability in drug 
types taken by males and females as impacting upon risk of death following IDO. However, as female 
fatality risk was elevated for all drug groups examined except illicit drugs, drug type is unlikely to account 
for the greater risk of a fatal outcome following overdose among males. To this end, more research is 
needed to elucidate the mechanisms that explain gender differences in fatality risk following IDO.  
Fatal IDO cases in this study were older than non-fatal cases. Lower case fatality in younger age has 
been attributed to better overall health status, lesser suicidal intent and increased chance of survival, 
compared to older persons (Jansen, et al., 2009). Conversely, accessibility to prescribed medications 
and better knowledge of the lethality of medications among older people has been used to explain their 
increased risk of fatality following IDO (Schmidtke, 2004). Considering the finding by Chen et al., 2009 
that the effect of age on fatality is stronger for poisoning compared to other methods of self-harm (Chen, 
et al., 2009), the link between growing age and increasing fatality, identified by this study, is an important 
consideration for the prevention of suicide by IDO in older persons. Prescribers should remain cognisant 
of the medication load of older patients and monitor for and respond to indicators of drug misuse within 
this subgroup. In particular, prescribing of drugs including those with established toxicity, should be 
reviewed before long term-use is established to ensure patient safety which in which the therapeutic 
effects are balanced against the risk of potential harm from such drugs (Bedson, et al., 2019).  
The involvement of multiple drugs in almost half of all non-fatal IDOs and approximately 80% of fatal 
IDOs identified in this study is significantly greater than found in previous comparative studies 
(Finkelstein, et al., 2016; HRB, 2015; Vancayseele, et al., 2016). Considering that the fatality of an IDO 
increases significantly as the number of drugs used in combination increases, the importance of 
restricting or avoiding multiple drug prescribing, when possible, is indicated by our findings. As 
successful suicide prevention required multiple level interventions, such means restriction measures 
should also be accompanied by treatments at individual level, to be provided by the mental health and 
allied services, including patient education, effective pharmacological and psychological treatments 
(Zalsman, et al., 2016).  
Strengths and limitations 
Our study has important strengths, including the use of robust national data covering an eight-year 




IDO presentations and all deaths due to IDO, respectively, is a unique strength of this study. The 
examination of case fatality of both single and multiple drug IDOs, and the novel analytical approach 
used to test case fatality estimates paves the way for future researchers to expand beyond 
examinations of fatality following single drug overdose. Furthermore, the examination of drugs identified 
as being a cause of death (as determined by the Coroner) and those involved in death (as indicated in 
toxicology) adds to the robustness of our findings and strengthens the conclusions drawn.  
The results of this study should be interpreted in the context of its limitations. Owing to the absence of 
a common unique patient identifier in both datasets examined it was not possible to perform data 
linkage. Thus, the case fatality risks reported represent an approximation of fatality risk between 
unlinked non-fatal and fatal IDO cases. Confounding by indication an important consideration when 
interpreting the study findings, as persons taking drugs with high case fatality estimates may indeed 
have had an initial higher risk of death prior taking these drugs, due to pre-existing physical or mental 
illnesses. This study examined non-fatal IDO episodes that resulted in hospital presentation, thereby 
excluding those that entailed general practice presentation only or those that go untreated by any 
healthcare professional. The NSHRI collects only information pertaining to treatment allocated in the 
emergency department, and it is therefore possible that persons who presented following non-fatal IDO 
may have subsequently died post-discharge or following recommended next care and potentially 
featured in our fatal IDO sample. Information collected on drugs used and quantity of tablets consumed 
in IDO was self-reported by the presenting individual, which may be subject to inaccuracy; however, 
these data are supplemented by ambulance service records, hospital medical records and toxicology 
reports where present. Finally, the certification of a drug as causal to death is established by the 
Coroner, using information obtained from the State Pathologist and State Laboratory for Human 
Toxicology, whereby the decision is based on the interoperation of the Coroner and thus may be 
subjective and not uniform across coronial districts.  
Conclusion 
Male gender, increasing age and multiple drug use were associated with fatal IDO. Tricyclic 
antidepressants and opioids were associated with significant elevations in risk of a fatal outcome 
following IDO. These findings add to the current evidence regarding the risk and potential adverse 




consider the fatality risk of drugs when determining treatment for patients at risk of self-harm or who 
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Figure 1a: Incidence rates of non-fatal intentional drug overdose, per 100,000 persons with 95% confidence intervals, by gender and age group, 2007-2014 
  
































































Table 1: Case fatality risks and case fatality risk ratios by demographic and intentional drug overdose characteristics, 2007-2014 
Characteristics All IDOs 2 Fatal IDOs1 
 
Case fatality risk % Case fatality risk ratio (95% CI) 
Gender Female 37202 163 0.4 *** Reference 
Male 26993 201 0.7 1.70 (1.38-2.09) *** 
Age group 15-24 years 18820 35 0.2 *** Reference 
25-44 years 29795 166 0.6 3.00 (2.08-4.31) *** 
≥45 years 15580 163 1.0 5.63 (3.91-8.11) *** 
IDO type Single drug IDO 32931 79 0.2 *** Reference 
Multiple drug IDO 31260 285 0.9 3.80 (2.96-4.88) *** 
Number of drugs 1 32931 79 0.2 *** Reference 
2-5  30895 232 0.8 3.13 (2.43-4.04) *** 
≥6  365 53 14.5 60.5 (42.7-85.7) *** 
Alcohol 
involvement 
Yes 27656 151 0.5 Reference  
No 36539 213 0.6 1.07 (0.87-1.32) 
1 Fatal IDOs include all IDOs which resulted in death within the study. 
2 All IDOs include all fatal and non-fatal IDOs within the study.  





Table 2: The number and rates of non-fatal and fatal intentional drug overdose where the drug caused death, and the associated case fatality risk and case 
fatality risk ratios, by gender, 2007-2014 
Drug All IDOs 1 Fatal IDOs 2 Case fatality  
Number Rate per 100,000 (95% CI) Number Rate per 100,000 (95% CI) Case fatality risk % Case fatality risk ratio (95% CI) 
Both genders 
Psycholeptics3 27970 77.6 (76.7-78.5) 166 0.46 (0.39-0.53) 0.69 (0.56-0.84) *** 2.41 (1.65-3.52) *** 
    Antipsychotics 6589 18.3 (17.8-18.7) 55 0.15 (0.11-0.19) 0.64 (0.46-0.90) ** 3.28 (2.14-5.02) *** 
    Anxiolytics 14778 41.0 (40.3-41.7) 78 0.22 (0.17-0.27) 0.57 (0.44-0.76) *** 2.08 (1.39-3.10) *** 
    Hypnotics and sedatives 13130 36.4 (35.8-37.1) 96 0.27 (0.21-0.32) 0.64 (0.49-0.82) *** 2.89 (1.94-4.31) *** 
        Benzodiazepines 24626 68.3 (67.5-69.2) 136 0.38 (0.31-0.44) 0.64 (0.51-0.79) *** 2.16 (1.48-3.16) *** 
Psychoanaleptics4 13797 38.3 (37.6-38.9) 141 0.39 (0.32-0.45) 0.75 (0.61-0.94) ** 4.41 (3.03-6.42) *** 
    Antidepressants 13600 37.7 (37.1-38.4) 141 0.39 (0.33-0.46) 0.75 (0.61-0.94) ** 4.46 (3.06-6.49) *** 
        Tricyclics 1307 3.63 (3.43-3.83) 52 0.14 (0.10-0.18) 0.89 (0.62-1.29) 15.1 (9.90-23.2) *** 
        SSRIs 7669 21.3 (20.8-21.8) 56 0.16 (0.11-0.20) 0.69 (0.49-0.97) * 3.15 (2.09-4.75) *** 
Opioids 2830 7.85 (7.56-8.15) 79 0.22 (0.17-0.27) 0.84 (0.62-1.12)  12.9 (8.60-19.3) *** 
Non-opioid analgesic 18031 50.0 (49.3-50.8) 40 0.11 (0.08-0.15) 0.35 (0.24-0.50) Reference 
Antiepileptics 4634 12.9 (12.5-13.2) 25 0.07 (0.04-0.10) 0.63 (0.38-1.04)  1.96 (1.17-3.29) ** 
Illicit drugs 3944 10.94 (11.3-10.9) 34 0.09 (0.06-0.13) 0.72 (0.46-1.11) 4.02 (2.36-6.86) *** 
Males 
Psycholeptics 12205 68 (66.8-69.2) 87 0.48 (0.39-0.59) 0.66 (0.50-0.87) 1.98 (1.20-3.26) ** 
    Antipsychotics 2763 15.4 (14.8-16) 20 0.11 (0.06-0.16) 0.51 (0.30-0.87) ** 1.89 (1.01-3.52) * 
    Anxiolytics 6744 37.6 (36.7-38.5) 39 0.22 (0.15-0.29) 0.56 (0.38-0.82) ** 1.58 (0.93-2.69) 
    Hypnotics and sedatives 5336 29.7 (28.9-30.5) 49 0.27 (0.19-0.35) 0.67 (0.47-0.96) * 2.49 (1.47-4.21) *** 
        Benzodiazepines 10797 60.1 (59.0-61.3) 70 0.39 (0.30-0.48) 0.63 (0.47-0.85) ** 1.76 (1.06-2.91) * 
Psychoanaleptics 4967 27.7 (26.9-28.5) 57 0.32 (0.23-0.40) 0.70 (0.50-0.98) * 3.10 (1.87-5.15) *** 
    Antidepressants 4868 27.1 (26.3-27.9) 57 0.32 (0.23-0.40) 0.70 (0.50-0.98) * 3.14 (1.89-5.22) *** 
        Tricyclics 472 2.63 (2.39-2.87) 17 0.09 (0.05-0.14) 0.89 (0.46-`.69) 9.02 (4.74-17.19) *** 




Opioids 1175 6.55 (6.16-6.93) 43 0.24 (0.17-0.31) 0.81 (0.54-1.20) 11.1 (6.47-19.1) *** 
Non-opioid analgesic 6213 34.6 (33.7-35.5) 22 0.12 (0.07-0.17) 0.33 (0.21-0.54) *** Reference 
Antiepileptics 1805 10.1 (9.6-10.5) 12 0.07 (0.03-0.11) 0.76 (0.36-1.60) 1.69 (0.83-3.41) 
Illicit drugs 2897 16.1 (15.5-16.7) 30 0.17 (0.11-0.23) 0.72 (0.45-1.16)  4.20 (2.27-7.76) *** 
Females 
Psycholeptics 15615 85.9 (84.5-87.2) 79 0.43 (0.34-0.53) 0.72 (0.54-0.96) * 2.91 (1.63-5.19) *** 
    Antipsychotics 3826 21 (20.4-21.7) 35  0.19 (0.13-0.26) 0.75 (0.49-1.17) 5.34 (2.89-9.85) *** 
    Anxiolytics 8034 44.2 (43.2-45.2) 39 0.21 (0.15-0.28) 0.60 (0.40-0.89) ** 2.77 (1.51-5.08) *** 
    Hypnotics and sedatives 7794 42.9 (41.9-43.8) 47 0.26 (0.18-0.33) 0.61 (0.42-0.87) ** 3.44 (1.87-6.35) *** 
        Benzodiazepines 13829 76 (74.7-77.3) 66 0.36 (0.27-0.45) 0.64 (0.47-0.87) ** 2.69 (1.50-4.83) *** 
Psychoanaleptics 8830 48.6 (47.5-49.6) 84 0.46 (0.36-0.56) 0.79 (0.60-1.06) 6.32 (3.57-11.2) *** 
    Antidepressants 8732 48 (47.0-49.0) 84 0.46 (0.36-0.56) 0.79 (0.60-1.06)  6.37 (3.60-11.3) *** 
        Tricyclics 835 4.59 (4.27-4.91) 35 0.19 (0.13-0.26) 0.90 (0.57-1.41) 23.6 (13.0-43.0) *** 
        SSRIs 5014 27.6 (26.8-28.3) 27 0.15 (0.09-0.21) 0.72 (0.45-1.16) 3.32 (1.80-6.13) *** 
Opioids 1655 9.10 (8.65-9.55) 36 0.20 (0.13-0.26) 0.88 (0.56-1.37) 15.4 (8.38-28.2) *** 
Non-opioid analgesic 11758 64.6 (63.5-65.8) 18 0.10 (0.05-0.15) 0.37 (0.21-0.63) *** Reference 
Antiepileptics 2829 15.6 (15.0-16.1) 13 0.07 (0.03-0.11) 0.55 (0.28-1.07) 2.40 (1.19-5.15) * 
Illicit drugs 1047 5.76 (5.40-6.11) <5 - 0.67 (0.19-2.38) 3.29 (1.00-10.8) * 
1 All IDOs include fatal and non-fatal IDOs where the drug did not cause death. 
2 Fatal IDOs include fatal IDOs where the drug caused death.  
3 Psycholeptics are psychoactive drugs used to depress mental activity and include antipsychotics, anxiolytics, and hypnotics and sedatives. 
4 Psychoanaleptics are stimulant drugs including antidepressants, psychostimulants, nootropics anti-dementia drugs and combinations with psycholeptics. 
The case fatality risk ratio presented here is weighted and thus involves analyses whereby the drug of interest is counted as half within the reference drug group (e.g. non-opioid analgesics) and half 
within the drug group of interest. The process of weighting was performed to address the challenge of calculating case fatality risk ratios when multiple drugs caused death. 
The case fatality risk ratios presented for both genders are adjusted for age. 









Table 3: The numbers and rates of non-fatal and fatal intentional drug overdose where individual drug caused death, and the associated case fatality risk and 
case fatality risk ratios (95% confidence intervals), by gender, 2007-2014 
 
Drug All IDOs 1 Fatal IDOs 2 Case fatality  
Number Rate per 100,000 (95% CI) Number Rate per 100,000 (95% CI) Case fatality risk % Case fatality risk ratio (95% CI) 
Both genders 
Tricyclics 
     Amitriptyline 784 2.18 (2.02-2.33) 37 0.10 (0.07-0.14) 0.89 (0.58-1.38) Reference 
     Dosulepin 288 0.80 (0.70-0.89) 13 0.04 (0.02-0.06) 0.91 (0.44-1.92) 0.93 (0.49-1.76)  
     Trimipramine 58 0.16 (0.12-0.20) <5 - 1.04 (0.15-7.35) 0.71 (0.18-3.02)  
SSRIs 
     Fluoxetine 1640 4.55 (4.33-4.78) 9 0.02 (0.01-0.04) 0.91 (0.37-2.23) Reference 
     Citalopram 1279 3.55 (3.35-3.75) 41 0.11 (0.08-0.15) 0.73 (0.49-1.09) 5.26 (2.55-10.85) *** 
     Sertraline 1014 2.81 (2.64-2.99) <5 - 0.45 (0.14-1.46) 0.74 (0.23-2.39) 
Opioids 
     Tramadol 1778 4.93 (4.70-5.17) 32 0.09 (0.06-0.12) 0.89 (0.53-1.34)  Reference 
     Oxycodone 287 0.80 (0.70-0.89) 24 0.07 (0.04-0.09) 0.98 (0.57-1.70) 3.94 (2.30-6.77) *** 
     Morphine 133 0.37 (0.31-0.43) 12 0.03 (0.01-0.05) 0.81 (0.39-1.69) 4.16 (2.11-8.19) *** 
Males 
Tricyclics 
     Amitriptyline 274 1.53 (1.34-1.71) 10 0.06 (0.02-0.09) 0.81 (0.35-1.84) Reference 
     Dosulepin 106 0.59 (0.48-0.71) 6 0.03 (0.01-0.06) 1.06 (0.34-3.29)  1.41 (0.51-3.89) 
     Trimipramine 21 0.12 (0.07-0.17) <5 - 10.5 (0.66-16.8) 1.26 (0.16-9.86) 
SSRIs 
     Fluoxetine 550 3.06 (2.80-3.33) <5 - 1.01 (0.25-4.03) Reference 
     Citalopram 449 2.50 (2.27-2.74) 20 0.11 (0.06-0.16) 0.76 (0.43-1.35) 5.90 (2.01-17.28) *** 
     Sertraline 323 1.80 (1.60-2.00) <5 - 0.38 (0.10-1.45) 1.28 (0.29-5.28)  
Opioids 




     Oxycodone 137 0.76 (0.63-0.89) 11 0.06 (0.02-0.10) 1.00 (0.44-2.28) 3.11 (1.45-6.66) ** 
     Morphine 80 0.45 (0.35-0.55) 6 0.03 (0.01-0.06) 0.63 (0.23-1.71)  2.85 (1.12-7.28) * 
Females 
Tricyclics 
     Amitriptyline 510 2.80 (2.56-3.05) 27 0.15 (0.09-0.21) 0.93 (0.55-1.55) Reference 
     Dosulepin 182 1.00 (0.85-1.15) 7 0.04 (0.01-0.07) 0.82 (0.30-2.20) 0.73 (0.32-1.68)  
     Trimipramine 37 0.20 (0.14-0.27) <5 - 1.03 (0.64-16.43) 0.51 (0.69-3.76) 
SSRIs 
     Fluoxetine 1090 6.0 (5.63-6.36) 5 0.03 (0.00-0.05) 0.84 (0.26-2.75) Reference 
     Citalopram 830 4.56 (4.25-4.88) 21 0.12 (0.07-0.17) 0.70 (0.40-1.22) 4.69 (1.76-12.49) ** 
     Sertraline 691 3.80 (3.51-4.09) <5 - 1.00 (0.06-16.01) 0.32 (0.04-2.70) 
Opioids 
     Tramadol 1064 5.85 (5.49-6.21) 15 0.08 (0.04-0.13) 0.85 (0.43-1.68) Reference 
     Oxycodone 150 0.82 (0.69-0.96) 13 0.07 (0.03-0.11) 0.96 (0.46-2.02) 5.06 (2.33-11.0) *** 
     Morphine 53 0.29 (0.21-0.37) 6 0.03 (0.01-0.06) 1.13 (0.36-3.50) 6.67 (2.54-17.5) *** 
1 All IDOs include fatal and non-fatal IDOs where the drug did not cause death. 
2 Fatal IDOs include fatal IDOs where the drug caused death.  
The case fatality risk ratio presented here is weighted and thus involves analyses whereby the drug of interest is counted as half within the reference drug group (non-opioid analgesics) and half 
within the drug group of interest. The process of weighting was performed to address the challenge of calculating case fatality risk ratios when multiple drugs caused death. 
The case fatality risk ratios presented for both genders are adjusted for age. 
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